hormone (GH) [i_3].14
Serum IGF-I concentrations are highly dependent on GH secretion, and measurement of serum IGF-I concentration is an important component in the clinical evaluation of GH-related disorders [4] [5] [6] [7] [8] [9] . In serum and other biological fluids, IGF-I is associated with high-affinity binding proteins (IGFBPs), which are numbered according to the sequence of published characterization. Six structurally homologous IGFBPs have been identified, each of which has distinct tissueexpressionand function [10] [11] [12] [13] [14] [15] .
Most (>75%) of the serum IGF-I circulates in a relatively stable 150-Wa ternary complex consisting of IGFBP-3 and a unique leucine-rich, acid-labile subunit. Smaller proportions of IGF-I are associated with the other binding proteins and <1% of serum IGF-I is estimated to exist in a "free" or unbound form. The IGFBPs appear to play important roles in a complex system that modulates the actionsof IGF-I and the relatedpeptide, IGF-II.
The high levels of association with IGFBPs complicate the routine measurement of serum IGF-I concentrations because the IGFBPs may mask reactive epitopes or compete with antibodies in an immunoassay.
Reliable determination of IGF-I in serum requires dissociation and removal of IGFBPs before analysis [5] . Present strategies are based on serum acidification to irreversibly denature the acid-labile subunit and disrupt the ternary complex, followed by procedures to remove most or all of the IGFBPs. Size-exclusion chromatography in acid is considered the "gold standard" method for the latter step [16] but may not be practical for efficient high-volume sample processing. The most commonly used alternative is ethanol precipitation [17] ; however, this method may leave substantial residual amounts of IGFBPs, which interfere in competitive immunoassays [18] and thus adversely affect the reliability of the measurements.
We report the development and performance characteristics of a new dual-epitope, noncompetitive ELISA for human IGF-I. The format of this assay is similar to a previously reported ' IRMA [19] . We also present comparisons of serum extraction methods by acid-gel chromatography, acid-ethanol precipitation, and a centrifugal acid-gel filtration method. human amniotic fluid according to previously described methods [20, 21] . Mouse monoclonal antibodies to human IGF-I
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MATERIALS
were from DSL.
ELISA FOR IGF-I
The IGF-I ELISA buffer contained 0.05 mollL Tris-maleate (pH 7.0), 9 g/L NaCl, 5 g/L bovine serum albumin (BSA), and 0.1 g/L thimerosal. The antibody-HRP conjugate buffer contained 0.02 mol/L sodium phosphate (pH 7.0), 9 g/L NaC1, 1 g/L CaCl,, 5 g/L BSA, and 0.1 g/L thimerosal. The stopping solution was 2 molJL sulfuric acid in deionized water. The compositions of the coating and blocking buffers and the wash solution were as described previously [22] .
IGF-I capture antibody was coated onto microtiter wells at a concentration of 5 mg/L by using previously published methods [22] . In brief, 0.1 mL of the capture antibody solution was added to each microwell and allowed to incubate overnight at room temperature.
The wells were then washed once with the wash solution; then 0.2 mL/well of the blocking solution was added and allowed to incubatefor 1 h as above.The wellswere washed once before use.
The IGF-I detection antibody was coupled to HRP as described previously [23] . ELISA kit (DSL). In brief, samples diluted 100-fold in the zero calibrator of the assay(0.025mL) and the assaybuffer(0.05mL) were added to microtiterwells precoated with purifiedanti-IGFBP-3 antibody and incubated at room temperature for 2 h on a shaker platform. The wells were washed, incubated with an anti-IGFBP-3 antibody-HRP conjugate solution for 1 h at room temperature, then washed and developed with the TMB chromogen and sulfuric acid stop solutions included in the kit.
Calibratorsranged from 2 to 100 g/L. IntraassayCVs were 9.5%, 9.4%, and 7.3% at 4.6, 27.4, and 74.4 p.g/L, and interassay CVs were 11.3%, 10.4%, and 8.2% at 5.6,25.1,and 65.6 pg/L, respectively. There was no measurable cross-reactivity with IGFBP-1 and no assayinterference with excess IGF-I or IGF-II. Assay sensitivity was 0.04 jig/L (1 pg/well).
Absorbances for allELISAs were measured with the Labsystems Multiskan Multisoft microplate reader (Labsystems, Helsinki, Finland).
SAMPLE PREPARATION PROCEDURES
Molecular sieve chromatography. To study the distribution of the immunoreactive substances in serum, 0.2 mL of serum containing -450 g/L IGF-I was subjected to size-exclusion chromatography on a precalibrated 600 X 7.5 mm Bio-Sil SEC-250 HPLC column (Bio-Rad). The column was preequilibrated and eluted with 0.05 molIL Tris-HC1 (pH 7.2)containing9.0 g/L NaC1 at 0.5 mL/min with collectionof 0.5-mL fractions. Distributionof IGF-I immunoreactivity was determined by extracting a 50-j.tL aliquot of each fraction by the acid-ethanol method described below, followed by IGF-I ELISA.
Acid-gelfiltration chromatography.
Size-exclusion chromatography of acidified serum samples was performed with the Bio-Sil SEC-250 HPLC column described above. The column was preequilibrated and eluted with 1.0 molJL acetic acid containing 0.1 mollL NaC1. Each serum sample (0.1 mL) was preincubated with 0.4 mL of 1.25 molfL acetic acid containing 0.125 mol/L NaC1 at room temperature for 15 mm. The column was loaded with 0.2 mL of the acidified sample and elutedat 1.0 mL/min with collection of 1.0-mL fractions. Each fraction was immediately neutralized with 1.0 mL of 1.25 molJL Tris base followed by addition of 0.5 mL/tube of IGF-I ELISA calibrator buffer containing 6 g/L BSA. Samples were then stored at 4 #{176}C overnight before assay.The finalsample dilution factor was 62. 5 [26] . In brief, 10 g of Bio-Gel P-b (fine) was hydrated in 150 mL of 1 mol/L aceticacid, 0.1 molJL NaCl, followed by addition of 1.5 g of BSA. After removal of 30 mL of the supernatant,the gel slurrywas graduallyadded to a Bio-Spin column to a bed height of 4 cm, and the column was capped for storage. Before use,excessliquidwas removed by centrifugation for 7 mm at 3000 rpm. Each serum sample was prepared by adding 0.05 mL of serum to 0.20 mL of 1.25mollL aceticacid, 0.125 molJL NaC1 and incubated for 10 mm at room temperature; 0.05 mL of this preparation was applied to the prepared Bio-Spin column, centrifuged for 7 mm at 3000 rpm, and then centrifugedagain afteradding 0.05 mL of 1 molIL aceticacid, 0.1 mol/L NaCI. IGFBPs were eluted in these first two steps.
The collection tube was changed and the IGFs were then eluted.
Insteadof elutingthe IGF pool by adding 1.5mL of the elution buffer(1.0molIL aceticacid,0.1 moVL NaCl) per column [26] , IGFs were elutedin two steps by first adding 1.0 mL and then 0.5 mL of the elutionbuffer,centrifuging aftereach step. This modification was necessary because the loading volume of the column was not sufficient to allow addition of the recommended 1.5 mL per column all at once. All centrifugations continued for 5 mm at 3000 rpm in a swinging bucket rotor (Model TJ centrifuge;
Beckman Instruments, Fullerton, CA). Immediately after elution, 1.5 mL of 1.25 mol/L Tris base was added to each tube, mixed, and analyzed for IGF-I. The overall dilution factor was 300-fold. The intrarun CVs of six replicate applications of a sample containing -500 g/L IGF-I to six columns was --5%.
DATA ANALYSIS
IRMA and ELISA data were analyzed with data reduction packages included with the respectiveinstrumentation, both based on cubic spline(smoothed) curve fit. 
Results
IGF-I ELISA
We investigated the effect of various technical manipulations in the IGF-I ELISA format (data not shown). Optimal performance was achieved with a coating antibody concentration of 5 mg/L (500 ng/0.1 mL per well), a detection antibody-HRP conjugate concentration of 0.10-0.18 mg/L antibody (10-18 ng/0. 1 mL per well), a sample size of 0.02 mL/well, and room-temperature incubation times of 2 h for the assay and 10 mm for substrate development.
Among the variables examined, changes in the concentration of the antibody-HRP conjugate had the most dramatic effects on the sensitivity and dynamic range of the assay.Although the assay could be performed with a first-step incubation time as short as 30 mm, a 2-h incubation was required to achieve a delayed-sample addition effect of <10% [i.e., differences in assay results caused by a I-to 20-mm delay between the sample and detection antibody addition steps (data not shown)]. A typical calibration curve for the IGF-I ELISA is shown in Fig. 1 IGF-I (13 g/L aftercorrectionfor the 100-folddilutionfactor introduced by the extractionprocedure) that was tested.A similarresult was obtainedwhen samples were first subjected to acid-ethanol extractionand then serially diluted in the zero calibrator of the assay(datanot shown).
To evaluatethe molecular mass of the immunoreactivity detectedby the IGF ELISA, a freshserum sample was fractionated by molecular sieve chromatography under neutral conditions and fractions were analyzed in the IGF-I ELISA after acid-ethanol extraction. As expected, a major peak was detected at -150 kDa, corresponding to the molecular mass of the major Sample no. serum IGF complex (Fig.2) . A smaller peak was detected in the 23-45-Wa region, corresponding to IGF/IGFBP complexes. No significant immunoreactivity was detected in the fractions corresponding to free IGF-I. However, in samples that were first acidified to release IGF-I from IGFBPs and then subjected to acid-gel filtration chromatography, the major immunoreactivepeak shiftedto <10 Wa, corresponding to the expected molecular mass of freeIGF-I (7.5 Wa) (Fig.2) . was preferredto accommodate the dynamic range of the assay.
Therefore, ratios of 1:10,1:15,and 1:20were testedas described in Materials and Methods. The concentrations of residual IGFBP-l and IGFBP-3 in the extractswere measured by ELISA. As shown in Table 2 , the ratioof 1:20 was the most effective for IGFBP-3 removal. The mean of residual IGFBP-3 was 58 ± 20 g/L as compared with 210 ± 170 g/L with a 1:10 ratio, corresponding to 11.9% ± 12.0% and 2.9% ± 1.9% of the original unextracted IGFBP-3 concentrations, respectively. The change in the extraction ratio was less effective in removing IGFBP-b. As shown in Table 2 To further evaluate the effectiveness of the acid-ethanol extraction using the 1:10 extraction ratio, we analyzed six serum samples for residual IGFBP-l and IGFBP-3 before and after extraction. As shown in Fig. 3 p.g/L IGFBP-b also had no effect on IGF-I measurements with the 1:10 extractionratio (Table 3 ).The means of the duplicate measurements obtained before and after addition of the IGFBPs were not significantly different when assessed by ANOVA (P = 0.166). Collectively, these results indicate the tolerance of the IGF-I ELISA to substantial fluctuations in concentrations of
SAMPLE EXTRACTION PROCEDURES
IGFBPs that remain after acid-ethanol extraction. The standard acid-ethanol extraction procedure involves a 1:4 To assess whether changes in centrifugation conditions sample:acid-ethanol ratio. For the IGF-I ELISA, a higher ratio would affect the efficiency of the extraction method, sixserum samples in four separate sets were extractedwith the 1:10 extractionratio. Two setsof these samples were centrifuged at 10 000 rpm, one set for 3 mm and the other for 10 mm; the remaining two setswere centrifugedat 14 000 rpm foreither3 or 10 mm. Analysisof the supematants indicatedno significant differences in the apparent concentrationsof IGF-I or residual IGFBP-3 concentrations(datanot shown). A 3-mm centrifugation at 10 000 rpm was used in subsequent experiments.
The optimized acid-ethanolextractionprocedure described above was then compared with extractionby size-exclusion acid-HPLC and by Bio-Spin chromatography in 12 serum samples. After extraction, samples were assayed in the IGF-I ELISA. Table 4 Finally,the IGF-I ELISA was used to measure IGF-I concentrationsin samples containingrelatively high concentrationsof the low-molecular-mass IGFBPs. Serum samples from pregnant females (n = 2),neonates (n = 3),and patientswith renalfailure (n = 3) were subjectedto acid-ethanolextraction and acid-HPLC before analysis. Similar to the above findings ( (Fig.4) .
Discussion
The importance of precise and accurate assays for IGF-I is linked to the increased availability and therapeutic use of GH, which has created a need for more efficient means of identifying individuals who might benefit from GH therapy [6] [7] [8] [9] Although assays for GH have been availablefor many decades,directtesting of GH secretion has been problematic [8] . Physiologicsecretionisnormally episodic;therefore,pharmacologic stimulation testing, with associated morbidity, has been used. Diagnosticcutoffs for defining normal and abnormal GH concentrationshave been, for the most part,arbitrary; thisis further complicated by extreme variability in measured concentrations between different assay methods.
Finally, recent data suggest that "normal" GH concentrations do not necessarily exclude clinically significant deficiencies in IGF secretion [8] .
Because IGF-I is a major effector for GH, it has been proposed that measurement of IGF-I itself be used to define normal and abnormal bioactivity of the GHIIGF axis. In contrast to GH, serum IGF-I concentrations have long been recognized as being relatively stable [29] because of association with the ternary complex. A large body of evidence supports the hypothesis that serum IGF-I concentrations are reflective of GHIIGF axis status. However, measurement of serum IGF-I concentrations has presented technical difficulties due to the presence of the IGFBPs.
As we confirm in this report, the standard laboratory procedure of acid-ethanol extraction does not remove all IGFBPs [18, [30] [31] [32] . In particular, low-molecular-mass IGFBPs such as IGFBP-1 can be retained in substantial quantities. The IGFBPs thatremain in the sample could theoretically compete with the detection antibody in an IGF-I immunoassay. This is particularly a concern in competitive RJAs, where the amount of antibody and labeled IGF-I is small relative to the concentration of analyte and residual IGFBPs. This phenomenon may account for the well-known propensity of IGF-I RIAs to give false estimates of IGF-I concentrations in samples with high concentrations of endogenous IGFBPs [16, 18, 30, 32] . Various means have been devised to further minimize the interference of
